
Please try another search
Blue Water Vaccines, Inc. is a biotechnology company. It is focused on the research and development of transformational vaccines to prevent infectious diseases worldwide. Its vaccine platform has molecular properties that enables delivery of various antigens, which can be utilized to develop singular or multi-targeted vaccines. Its lead influenza (flu) vaccine program uses technology to identify specific epitopes, or proteins, with cross-reactive properties that enables the development of a universal flu vaccine. It is focused on developing novel vaccines that induce durable and long-term immunity. It is also utilizing its platform to develop a vaccine for the prevention of gastroenteritis cause by both norovirus and rotavirus. Its vaccine candidates include BWV-101 and BWV-102, an influenza vaccine program; BWV-201, which is a streptococcus pneumoniae (S. pneumoniae) vaccine program; BWV-301, a norovirus-rotavirus vaccine program, and BWV-302, a norovirus-malaria vaccine program.
Name | Age | Since | Title |
---|---|---|---|
Joseph Hernandez | 49 | 2018 | CEO, President & Executive Chairman |
James R. Sapirstein | 61 | 2022 | Independent Non-Executive Director |
John Mccune Rice | 72 | 2022 | Member of Scientific Advisory Board |
Simon Tarsh | 61 | 2022 | Independent Director |
David Zarley | - | - | Member of Scientific Advisory Board |
Sunetra Gupta | - | - | Member of Scientific Advisory Board |
Vuk Jeremic | - | 2022 | Director |
Timothy R. Ramdeen | - | 2023 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review